

## GenSight Biologics announces its 2018 Financial Calendar

**Paris, France, January 17, 2018, 7.30 am CET** – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced its financial calendar for 2018.

Information	Date*
2017 4Q Cash Position	January 25, 2018
2017 Full-Year Financial Update and Statements	February 28, 2018
Annual General Meeting	April 12, 2018
2018 1Q Cash Position	April 25, 2018
2018 First-Half Financial Update and Statements	July 25, 2018
2018 3Q Cash Position	October 24, 2018
2018 4Q Cash Position	January 23, 2019

\* This financial calendar is provided for information only, and may be subject to changes. The Company's updated financial calendar is available on its corporate website.

### Contacts

#### GenSight Biologics

Thomas Gidoïn  
Chief Financial Officer  
[tgidoïn@gensight-biologics.com](mailto:tgidoïn@gensight-biologics.com)  
+33 (0)1 76 21 72 20

#### RooneyPartners

Media Relations  
Marion Janic  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com)  
+1-212-223-4017

#### The Trout Group

US Investor Relations  
Chad Rubin  
[crubin@troutgroup.com](mailto:crubin@troutgroup.com)  
+1-646-378-2947

#### James Palmer

Europe Investor Relations  
[j.palmer@orpheonfinance.com](mailto:j.palmer@orpheonfinance.com)  
+33 7 60 92 77 74

### About GenSight Biologics

GenSight Biologics S.A. is a clinical-stage biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics' pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics to help preserve or restore vision in patients suffering from blinding retinal diseases. GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and young adults. Using its gene therapy-based approach, GenSight Biologics' product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery.